Hagop M. Kantarjian, MD, discusses 5-year OPTIC trial data supporting a response-based, dose-reduction strategy for ponatinib in chronic-phase CML.
Back
Achieving Optimal TKI Dosing in Chronic Myeloid Leukemia
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.
Achieving Optimal TKI Dosing in Chronic Myeloid Leukemia
Episodes
All
All
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia, according to data from OPTIC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5